Copanlisib
- Generic Name
- Copanlisib
- Brand Names
- Aliqopa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28N8O4
- CAS Number
- 1032568-63-0
- Unique Ingredient Identifier
- WI6V529FZ9
- Background
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was gr...
- Indication
Copanlisib is indicated for the treatment of adults with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. This indication was granted under accelerated approval; thus, continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Associated Conditions
- Relapsed Follicular Lymphoma
- Associated Therapies
- -
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaRecurrent Endometrial CarcinomaHigh Grade Ovarian Serous AdenocarcinomaProgressive DiseasePlatinum-Resistant Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma
- Interventions
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT03586661
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03581942
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited protocol Activities), Montvale, New Jersey, United States
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT03502733
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Christian Buske
- Target Recruit Count
- 36
- Registration Number
- NCT03474744
- Locations
- 🇦🇹
Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I, Wien, Austria
🇩🇪St. Josef-Hospital, Medizinische Klinik I, Bochum, Germany
🇩🇪Johanniter GmbH, Johanniter-Krankenhaus, Bonn, Germany
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03377101
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03128619
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
- Conditions
- Interventions
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Chonnam National University Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT03052933
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
- Conditions
- Interventions
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 11
- Registration Number
- NCT02822482
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest, Angers, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 11
- Registration Number
- NCT02728258
- Locations
- 🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 26
- Registration Number
- NCT02705859
- Locations
- 🇮🇪
Cancer Trials Ireland Investigative Site, Galway, Ireland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.